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Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders characterized by progressive spasticity of the lower
limbs due to degeneration of the corticospinal motor neurons. In a Bulgarian family with three siblings affected by complicated
hereditary spastic paraplegia, we performed whole exome sequencing and homozygosity mapping and identiﬁed a homozygous
p.Thr512Ile (c.1535C4T) mutation in ATP13A2. Molecular defects in this gene have been causally associated with Kufor-Rakeb
syndrome (#606693), an autosomal recessive form of juvenile-onset parkinsonism, and neuronal ceroid lipofuscinosis (#606693), a
neurodegenerative disorder characterized by the intracellular accumulation of autoﬂuorescent lipopigments. Further analysis of 795
index cases with hereditary spastic paraplegia and related disorders revealed two additional families carrying truncating biallelic
mutations in ATP13A2. ATP13A2 is a lysosomal P5-type transport ATPase, the activity of which critically depends on catalytic
autophosphorylation. Our biochemical and immunocytochemical experiments in COS-1 and HeLa cells and patient-derived ﬁbro-
blasts demonstrated that the hereditary spastic paraplegia-associated mutations, similarly to the ones causing Kufor-Rakeb syn-
drome and neuronal ceroid lipofuscinosis, cause loss of ATP13A2 function due to transcript or protein instability and abnormal
intracellular localization of the mutant proteins, ultimately impairing the lysosomal and mitochondrial function. Moreover, we
provide the ﬁrst biochemical evidence that disease-causing mutations can affect the catalytic autophosphorylation activity of
ATP13A2. Our study adds complicated hereditary spastic paraplegia (SPG78) to the clinical continuum of ATP13A2-associated
neurological disorders, which are commonly hallmarked by lysosomal and mitochondrial dysfunction. The disease presentation in
our patients with hereditary spastic paraplegia was dominated by an adult-onset lower-limb predominant spastic paraparesis.
Cognitive impairment was present in most of the cases and ranged from very mild deﬁcits to advanced dementia with fronto-
temporal characteristics. Nerve conduction studies revealed involvement of the peripheral motor and sensory nerves. Only one of
ﬁve patients with hereditary spastic paraplegia showed clinical indication of extrapyramidal involvement in the form of subtle
bradykinesia and slight resting tremor. Neuroimaging cranial investigations revealed pronounced vermian and hemispheric cere-
bellar atrophy. Notably, reduced striatal dopamine was apparent in the brain of one of the patients, who had no clinical signs or
symptoms of extrapyramidal involvement.
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Introduction
Hereditary spastic paraplegias (HSPs) are heterogeneous
neurodegenerative disorders characterized by progressive
spasticity of the lower limbs due to axonopathy of the cor-
ticospinal neurons. Clinically, HSPs are classiﬁed into pure
and complicated forms, the latter being associated with add-
itional neurological or non-neurological symptoms.
Mutations in over 60 genes are implicated in HSP, although
these only explain 30–70% of cases depending on the
mode of inheritance (Finsterer et al., 2012; Fink, 2013;
Crow et al., 2014; Lo Giudice et al., 2014; Schule et al.,
2016). Recent gene discoveries have revealed a genetic over-
lap between HSP and a spectrum of neuronopathies and
axonopathies (Peeters et al., 2013), supporting their clinical
similarity and common pathomechanistic background.
ATP13A2 (OMIM 610513) is a lysosomal P5-type
transport ATPase, for which the transported substrate re-
mains unidentiﬁed (van Veen et al., 2014). ATP13A2
undergoes catalytic autophosphorylation on Asp508
within the conserved P-type ATPase motif, which is regu-
lated by phosphatidic acid and phosphatidylinositol(3,5)-
bisphosphate (Holemans et al., 2015; Martin et al., 2015).
ATP13A2 offers cellular protection to heavy metal ions
(Mn2+, Fe3+, Zn2+) (Gitler et al., 2009; Schmidt et al.,
2009; Tan et al., 2011; Covy et al., 2012; Park et al.,
2014; Rinaldi et al., 2015; Martin et al., 2016), -synu-
clein (Gitler et al., 2009; Schultheis et al., 2013; Kong
et al., 2014) and mitochondrial toxicity (Grunewald
et al., 2012; Gusdon et al., 2012; Holemans et al.,
2015; Park et al., 2015; Martin et al., 2016). All of
these functions depend on the capability of ATP13A2 to
undergo autophosphorylation (Gitler et al., 2009; Schmidt
et al., 2009; Tan et al., 2011; Covy et al., 2012; Park
et al., 2014; Rinaldi et al., 2015).
Mutations in ATP13A2 have been initially associated
with Kufor-Rakeb syndrome (KRS) (Ramirez et al.,
2006), an autosomal recessive form of juvenile-onset par-
kinsonism that is typically accompanied by cognitive im-
pairment, supranuclear gaze palsy and signs or symptoms
of pyramidal degeneration. Reports of brain iron accumu-
lation in the putamen and caudate present in some patients
have also led to classiﬁcation of KRS as a form of neuro-
degeneration with brain iron accumulation (NBIA)
(Behrens et al., 2010; Schneider et al., 2010). Subsequent
studies have broadened the phenotypic spectrum of biallelic
ATP13A2 mutations to include also milder cases without
pyramidal or cognitive involvement (Di Fonzo et al., 2007).
Additionally, single heterozygous ATP13A2 variants may
represent risk factors for early- and late-onset parkinsonism
(Djarmati et al., 2009; Rakovic et al., 2009; Fei et al.,
2010; Park et al., 2015).
More recently, ATP13A2 mutations were identiﬁed in a
single kindred with neuronal ceroid lipofuscinosis (NCL)
(Farias et al., 2011; Bras et al., 2012; Schultheis et al.,
2013), histologically deﬁned by the presence of vacuolated
lymphocytes, cytoplasmic positive autoﬂuorescent lipopigments
and ﬁngerprint-like proﬁles in nerve and muscle biopsy (Tome
et al., 1985). The clinical presentation in this family showed
strong overlap with KRS and was characterized by combined
extrapyramidal, pyramidal and cerebellar involvement, accom-
panied by cognitive deﬁcits, peripheral neuropathy and slow
vertical eye movements (Bras et al., 2012).
Here, we report that mutations in ATP13A2 cause com-
plicated HSP type SPG78, further expanding the clinical
and genetic spectrum of ATP13A2-associated disorders,
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which are commonly characterized by lysosomal and mito-
chondrial dysfunction. We propose that loss of ATP13A2
autophosphorylation activity contributes to the loss of
ATP13A2 function and disease aetiology.
Materials and methods
Clinical and imaging evaluation
All patients received a systematic neurological and electro-
physiological assessment to evaluate affection of multiple
neurological systems by movement disorder specialists.
Routine brain MRI including T1-, T2, diffusion-weighted
images (DWI) and ﬂuid attenuated inversion recovery T2
(FLAIR) images were performed in all ﬁve cases and reviewed
by neuroradiologists and neurologists. Dopamine transporter
scintigraphy (DaTSCAN) with 185 MBq 123I-Ioﬂupan was
performed in Patient HIH21480.II.3. Images were acquired
with a dual-headed SPECT camera (E.CAM+ , Siemens
Healthcare) at 180min after bolus injection of 185 MBq
123I-FP-CIT (GE Healthcare Buchler). Image reconstruction
was performed using an iterative algorithm (2D Ordered
Subset Expectation Maximization, three iterations, eight sub-
sets). Images were interpreted both visually and quantitatively
with the Hermes Brass software package (Version 3.4.4,
Hermes Medical Solutions, Stockholm, Sweden).
Written informed consent was obtained from all patients and
the study was approved by the respective local institutional
review boards.
Whole exome sequencing and
homozygosity mapping
Genomic DNA was isolated from peripheral blood according
to standard procedures. The exomes of Patients HSP84.II.1,
HSP84.II.3, HIH21480.II.3 and HIH22132.II.1 were captured
by Agilent’s SureSelect Enrichment solution. Paired-end
sequencing on Hiseq2000/2500 platforms yielded 6Gb of
raw data, with 90% of the targets covered at least 20. The
sequencing reads were aligned to hg19 with the Burrows-
Wheeler aligner (Li and Durbin, 2009). Variant calling and
realignment was done by GATK (McKenna et al., 2010), sub-
sequent annotation and ﬁltering were performed with
GenomeComb package for genomic data analysis (Reumers
et al., 2012) (for Patients HSP84.II.1 and HSP84.II.3) and
Genesis (Gonzalez et al., 2015) (for Patients HIH22132.II.1
and HIH21480.II.3).
Homozygosity mapping was performed using SNPs ex-
tracted from whole exome sequencing data using the
HOMWES tool in GenomeComb (Kancheva et al., 2015).
Sanger sequencing and genetic
validation
Identiﬁed variants were validated by bidirectional Sanger
sequencing. The PCR products were puriﬁed with ExoSAP-
IT (USB), directly sequenced with a BigDye Terminator
v.3.1 kit (Applied Biosystems) and electrophoretically sepa-
rated on an ABI3730xl DNA Analyzer (Applied Biosystems).
Co-segregation analysis of the variants with the disease was
performed for all available family members. The novel muta-
tions were screened in unrelated control individuals.
Genetic nomenclature
Mutations were described according to the Human Genome
Variation Society nomenclature; transcript ATP13A2
(NM_001141973.2) was used as a reference.
DNA constructs
The hATP13A2-pDONR221 was previously described
(Holemans et al., 2015). Via Gateway subcloning ATP13A2
was transferred into pcDNA6-GFP-tag (N-terminal) or
pcDNA3 vectors. p.Phe177Leu, p.Thr512Ile, p.Gly528Arg,
p.Gln1135 mutations were introduced via QuickChange
Mutagenesis (Stratagene) and veriﬁed by Sanger DNA
sequencing.
Western blotting
Western blotting was performed as previously described
(Vandecaetsbeek et al., 2009). Membranes were probed with
anti-ATP13A2 rabbit polyclonal antibody (1:5000, A3361,
Sigma). Detection was performed via enhanced chemilumines-
cence (Pierce), which was visualized by a Bio-Rad ChemiDoc
TM
MP imager.
Cell cultures
Control, Thr512Ile and Phe851Cysfs6 ﬁbroblasts were main-
tained in BME media (Sigma), supplemented with 100 U/ml
penicillin, 100 mg/ml streptomycin, at 37C, 5% CO2. HeLa
and COS-1 cells were maintained in Dulbecco’s modiﬁed
Eagle medium containing 10% foetal calf serum, 4mM
GlutaMAXTM-I supplement, 100 U/ml penicillin, 100mg/ml
streptomycin and 0.1mM minimal essential medium non-es-
sential amino acids (Invitrogen) at 37C in an atmosphere of
air with 5% CO2.
Immunocytochemistry and fluores-
cence microscopy
Fibroblasts, COS-1 or HeLa cells were seeded on glass-bot-
tomed dishes and their lysosomes and mitochondria were
visualized with LysoTracker or MitoTracker probes accord-
ing to the manufacturer’s instructions (Life Technologies).
Additionally, control and Thr512Ile ﬁbroblasts were seeded
on 12mm diameter cover slips and 48 h later ﬁxed with ice-
cold methanol for 20min at 20C. Subsequently, the cells
were stained with anti-LAMP1 rabbit polyclonal antibody
(1:500, ab24170, Abcam), anti-TOMM20 mouse monoclonal
antibody (1:500, ab56783, Abcam), and secondary anti-rabbit
IgG Alexa Fluor 488 and anti-mouse IgG Alexa Fluor 594
antibodies (1:500, Life Technologies).
HeLa cells were transiently transfected with GFP-N-
ATP13A2 WT or Phe177Leu, Thr512Ile, Gln1135 using
Lipofectamine LTX reagent (Life Technologies), cultured on
glass-bottomed dishes for 48 h, and stained with LysoTracker
(Life Technologies).
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HeLa cells were transiently co-transfected with GFP-N-
ATP13A2 WT or mutants Phe177Leu, Thr512Ile and
Gln1135 together with pCI-mRuby-KDEL (ER marker)
using Lipofectamine LTX reagent (Life Technologies). Cells
were cultured on glass-bottomed dishes for 48 h and ﬂuores-
cent images were taken using a Zeiss LSM700 confocal
microscope.
Lysosomal area and mitochondrial
morphology
Lysosomal area ratio was measured in control and patient-
derived LysoTracker-stained ﬁbroblasts (Thr512Ile-HSP)
using ImageJ software (Schneider et al., 2012). The transmitted
light image was used to manually delineate the cell borders,
and for each cell the area covered with lysosomes was seg-
mented based on automatic intensity thresholding (Huang
method). Lysosomal area ratio was calculated by dividing
the lysosomal area by the total cell area for each cell. More
than 50 cells per genotype were analysed.
To compare mitochondrial morphology between control and
Thr512Ile-HSP ATP13A2 we quantitatively assessed mito-
chondrial morphology in ﬁbroblasts stained with
MitoTracker. Mitochondria were automatically detected
using an ImageJ script with a customized segmentation pro-
cedure, which combines global (Triangle method) and local
(Phansalkar method) automatic intensity thresholding, size-se-
lective Watershed algorithm and Boolean operations on the
binary masks. The shape factor (circularity) of over 30 000
individual mitochondrial segments originating from more than
200 cells was measured.
Lysosomal and mitochondrial
homeostasis
Thr512Ile-HSP, Phe851Cysfs6 and control ﬁbroblasts were
seeded in 12-well plates and allowed to adhere overnight at
37C. For mitochondrial functionality, cells were stained with
MitoTracker Deep RED FM (1 mM) or tetra-methylrhoda-
mine (TMRM, 1 mM) for 30min. Pretreatment with carbonyl
cyanide m-chlorophenyl hydrazone (CCCP, 1 mM) for 1 h prior
to staining was used as a positive control (Supplementary Fig.
1A). For lysosomal functionality cells were stained with either
LysoTracker RED (1 mM) for 1 h or DQ-BSA (1 mM) for 2 h.
Lysosomal function was monitored by the addition of
Baﬁlomycin A1 (Baf A1, 10 nM) at least 1 h prior to staining
(Supplementary Fig. 1B). Measurements for lysosomal and
mitochondrial mass were normalized to cell size whereby for-
ward scatter was used as a cell-size index. All samples were
detected using an Attune ﬂow cytometer (Becton Dickinson
Immunocytometry systems).
Transmission electron microscopy of
human fibroblasts
Thr512Ile-HSP and control ﬁbroblast primary cultures grown
on glass cover slips were ﬁxed in 4% paraformaldehyde and
2.5% glutaraldehyde in 0.1M sodium cacodylate buffer (pH
7.2) for 4 h at room temperature followed by ﬁxation over
night at 4C. After washing, cells were subsequently
dehydrated through a graded ethanol series, including a bulk
staining with 1% uranyl acetate at the 50% ethanol step fol-
lowed by embedding in Spurr’s resin.
Ultrathin sections of a gold interference colour were cut
using an ultra-microtome (Leica EM UC6), followed by a
post-staining in a Leica EM AC20 for 40min in uranyl acetate
at 20C and for 10min in lead stain at 20C. Sections were
collected on Formvar-coated copper slot grids. Grids were
viewed with a JEM 1400plus transmission electron microscope
(JEOL) operating at 60 kV.
Membrane fractionation
COS-1 cells were transiently transfected with GFP-N-
ATP13A2 WT or Phe177Leu, Thr512Ile, Gly528Arg,
Gln1135 using GeneJuice (Novagen) according to the manu-
facturer’s protocol. Forty-eight hours post-transfection, cells
were harvested and fractionated as previously described
(Vandecaetsbeek et al., 2009). To prepare total membrane
fractions, the lysates were ﬁrst cleared from the nuclear frac-
tion (1000g, 10min, 4C) and then centrifuged to collect the
total membranes (200 000g, 35min, 4C). Fractions were sus-
pended in 0.25M sucrose with SIGMAFAST
TM
protease inhibi-
tor cocktail (Sigma). Protein concentration was determined
with the Q-bit ﬂuorimetric method (Life Technologies).
Proteasome inhibition
COS-1 cells were transiently transfected with GFP-N-
ATP13A2 WT or Phe177Leu, Thr512Ile, Gly528Arg,
Gln1135 using GeneJuice (Novagen) according to the manu-
facturer’s protocol. MG132 (M7449, Sigma-Aldrich) was dis-
solved in dimethyl sulphoxide (DMSO) solution buffer and
used at 20mM for 6 h. DMSO was used as a control vehicle.
Autophosphorylation assay
Forty micrograms of COS-1 membranes were added to a ﬁnal
volume of 95 ml of EP reaction buffer (17mM HEPES pH 6.5,
160mM KCl, 2mM MgCl2, 1mM DTT, 5mM NaN3). The
reaction was initiated by addition of -32P-ATP (7.5 mCi) in a
ﬁnal ATP concentration of 5.125mM and stopped after 60 s by
adding 400 ml ice-cold stop solution (20% trichloroacetic acid,
10mM phosphoric acid). After precipitation on ice for 20min,
samples were centrifuged at 20 000g (30min, 4C). The pellet
was washed twice with 400ml ice-cold stop solution and dis-
solved in sample buffer (10% LDS, 10mM NaH2PO4, 0.01%
SDS, 10mM 2-mercaptoethanol, 0.5mg/ml bromophenol blue)
prior to acidic electrophoresis, as previously described
(Sorensen et al., 2012).
Statistics
Analysis of lysosomal and mitochondrial quantiﬁcation and
function in control versus Thr512Ile-HSP or Phe851Cysfs6
patient-derived ﬁbroblasts was performed using a two-sample
t-test. Relative expression levels and autophosphorylation in
ATP13A2 WT and mutants were analysed using an ANOVA
test with post hoc Bonferroni correction. All tests were two-
tailed and the level of signiﬁcance was set at P5 0.05.
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Results
Identification of HSP-associated
mutations in ATP13A2
We studied a Bulgarian family with three affected brothers
(Family HSP84, Fig. 1A) presenting an adult-onset HSP
phenotype, complicated by mild cognitive impairment, cere-
bellar ataxia, and axonal motor and sensory polyneurop-
athy (Table 1). Whole exome sequencing was performed on
Patients HSP84.II.1 and HSP84.II.3, followed by whole
exome sequencing-based homozygosity mapping. A total
of 75 shared autozygous regions were identiﬁed, encom-
passing 111Mb of genomic DNA. The whole exome
sequencing data were ﬁltered for homozygous variants
located within these regions with an impact on protein
structure (non-synonymous and/or affecting mRNA spli-
cing) and 45% frequency in dbSNP135 (Sherry et al.,
2001), EVS6500 [Exome Variant Server, NHLBI Exome
Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.
washington.edu/EVS/) (August 2014)], 1000 Genomes
(Genomes Project et al., 2015), and in-house exome/
genome databases (Gonzalez et al., 2015). Only one mis-
sense variant, c.1535C4T (p.Thr512Ile) in ATP13A2 ful-
ﬁlled these criteria. This variant co-segregated with the
disease (Fig. 1A) and was absent in 94 ethnically matched
controls. The p.Thr512Ile substitution (p.Thr512Ile-HSP)
targets a highly conserved amino acid (GERP score = 5.6)
(Cooper et al., 2005), affecting a residue in the autopho-
sphorylation motif (Fig. 1B), and is predicted to be deleteri-
ous by SIFT (Kumar et al., 2009), MutationTaster2
(Schwarz et al., 2014) and PolyPhen-2 (Adzhubei et al.,
2010). Surprisingly, the same mutation had previously
been described to cause KRS in a sporadic Lebanese
patient (p.Thr512Ile-KRS; nomenclature in original publi-
cation: NM_022089.2: c.1550C4T, p.Thr517Ile)
(Dehay et al., 2012; Grunewald et al., 2012; Usenovic
et al., 2012).
To obtain additional genetic evidence on the causal link
between ATP13A2 and HSP, we screened a cohort of 795
index cases with phenotypes overlapping the clinical mani-
festation in Family HSP84. This cohort comprised cases
with pure or complicated HSP, ataxia and axonal neur-
opathy (Supplementary Table 1). To test the speciﬁcity of
ATP13A2 mutations for this phenotypic spectrum, we add-
itionally screened 1985 patients with autosomal recessive
non-overlapping neurological and non-neurological pheno-
types including cases with late-onset Alzheimer’s disease,
amyotrophic lateral sclerosis, epileptic encephalopathy, car-
diomyopathy, deafness and ocular phenotypes (Gonzalez
et al., 2015).
Among the 795 cases with overlapping phenotypes we
identiﬁed two additional families with autosomal-recessive
complicated HSP and ATP13A2 mutations, while no bial-
lelic mutations were found in the non-overlapping neuro-
logical and non-neurological phenotypes. A homozygous
c.364C4T (p.Gln122) variant was found in a Serbian
family (HIH21480). This nonsense mutation introduces a
premature stop codon in the ﬁfth exon of ATP13A2. In the
Bosnian HIH22132 family, two nonsense mutations
[c.1330C4T (p.Arg444) and c.3403C4T
(p.Gln1135)] were conﬁrmed by Sanger sequencing
(Fig. 1A).
Clinical findings
The disease presentation in all ﬁve cases was dominated by
an adult onset (mean 32 years) combined pyramidal-cere-
bellar syndrome that led to the clinical diagnosis of com-
plicated HSP, which progressed rapidly (Table 1).
Cognitive deﬁcits were present in four of ﬁve cases but
ranged from very mild deﬁcits to advanced dementia with
fronto-temporal characteristics (Patient HIH22132.II.1).
Supranuclear gaze palsy was noted in two cases. Nerve
conduction studies revealed predominantly axonal sen-
sory-motor peripheral neuropathy in four out of ﬁve indi-
viduals. Only one of the ﬁve cases showed clinical
indication of extrapyramidal involvement in the form of
very mild bradykinesia and slight resting tremor (Patient
HIH22132.II.1) that didn’t interfere with the activities of
daily living.
The most striking ﬁnding on MRI was a progressive ver-
mian and hemispheric cerebellar atrophy (Fig. 2A–C),
accompanied by a less pronounced cortical atrophy and
mild periventricular white matter changes in some cases.
In two cases (Patients HSP84.II.3 and HIH22132.II.1) an
‘ear of the lynx’ sign (Riverol et al., 2009) and T2 hyper-
intensities of the anterior fornix of the corpus callosum
were noted (Fig. 2A and B). In one case (Patient
HIH21480.II.3) thinning of the corpus callosum, periven-
tricular white matter changes and a hydrocephalus internus
were additionally present (Fig. 2C). Prompted by the iden-
tiﬁcation of ATP13A2 mutations, we performed a
DaTSCAN (123I-FP-CIT) in Patient HIH21480.II.3 to
evaluate presynaptic dopamine transporter density in the
striatum (Fig. 2D). Although Patient HIH21480.II.3
showed no clinical signs or symptoms of extrapyramidal
involvement, the DaTSCAN revealed a drastic decrease of
dopamine transporter density, most pronounced in the
putamen.
Functional evaluation of HSP-asso-
ciated ATP13A2 mutations
In ﬁbroblasts of a known KRS patient, the p.Thr512Ile-
KRS mutation affects both lysosomal function and mito-
chondrial network integrity (Dehay et al., 2012;
Grunewald et al., 2012; Usenovic et al., 2012). Since we
now identiﬁed the same mutation in patients with compli-
cated HSP (p.Thr512Ile-HSP), we evaluated ﬁbroblasts iso-
lated from Patient HSP84.II.2. Lysosomes in patient and
control ﬁbroblasts were visualized by the lysosomal mar-
kers LysoTracker (Fig. 3A) and LAMP1 (Supplementary
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Figure 1 Novel mutations in ATP13A2. (A) Graphic representation of three autosomal recessive families with complicated HSP in which
ATP13A2 mutations were identified. Sanger sequencing traces confirming the presence of the mutations are presented and their segregation in
available family members is demonstrated. The symbol ( + ) represents wild-type. Blackened symbols indicate affected individuals and symbols with
slashes depict deceased individuals. (B) Amino acid conservation of ATP13A2 polypeptide in different species, the black frame delimits the
autophosphorylation motif (508DKTGT), catalytic conserved residues Asp508 and Thr512 in human ATP13A2 are indicated by black arrows.
Below the alignment, asterisk indicates fully conserved, colon indicates strongly similar, and full stop indicates weakly similar amino acids.
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Fig. 2). Compared to controls, we observed a signiﬁcant
increase in the amount of lysosomes per cell (Fig. 3A), as
seen before in ﬁbroblasts from the Thr512Ile-KRS patient
(Dehay et al., 2012). Furthermore, via LysoTracker Red-
based ﬂow cytometry we detected an increase in lysosomal
mass in Thr512Ile-HSP compared to control ﬁbroblasts
(Fig. 3B). The lysosomal functionality was also compro-
mised, as there was a signiﬁcant reduction in the proteolytic
activity, which was assessed by the capability of processing
the DQ-BSA substrate into a ﬂuorescent product (Fig. 3C).
A similar lysosomal phenotype was also observed in ﬁbro-
blasts derived from a KRS patient carrying a known
truncating p.Phe851Cysfs6 mutation in ATP13A2 (Fig.
3B and C) (Crosiers et al., 2011).
The mitochondrial network in the Thr512Ile-HSP and
control ﬁbroblasts was visualized using the mitochondrial
markers MitoTracker and TOMM20 (Fig. 3D and
Supplementary Fig. 2). In contrast to the ﬁndings of
Grunewald et al. (2012), mitochondrial fragmentation or
swelling was not markedly present in patient ﬁbroblasts.
Also a quantitative comparison of mitochondrial circularity
did not reveal differences in mitochondrial morphology be-
tween patient-derived and control cells. However, ﬁbro-
blasts carrying p.Thr512Ile-HSP mutation displayed a
Figure 2 Cranial imaging in ATP13A2 HSP cases. Routine MRI in Patients HIH22132.II.1 (A) (disease duration 7 years), HSP84.II.3 (B)
(disease duration 7 years), and HIH21480.II.3 (C) (disease duration 11 years). Images demonstrate vermian (white arrow) as well as hemispheric
cerebellar atrophy (white arrowheads) that was progressive over time in Patient HIH22132.II.1 (not shown). Generalized cortical atrophy was
present in all cases. In Patients HIH22132.II.1 (A) and HSP84.II.3 (B) an ‘ear of the lynx’ sign (T2 hyperintensity of the anterior fornix of the corpus
callosum, marked by an asterisk) was present, while periventricular white matter changes were more pronounced in Patient HIH21480.II.3 (C).
The latter case also demonstrated thinning of the corpus callosum (C, marked by black arrow). (D) Transversal fused 123I-FP-CIT SPECT and T2-
weighted MRI images of three representative sections of the striatum in Patient HIH21480.II.3 (red box) and a representative section of the
striatum from a healthy adult (green box, far right). Patient HIH21480.II.3 demonstrates severely reduced striatal dopamine.
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Figure 3 Functional characterization of ATP13A2 mutant proteins. (A) Lysosomes of control and patient-derived (Patient HSP84.II.2)
fibroblasts were stained with LysoTracker (left), along with quantification of the lysosomal area ratio (lysosomal area/total cell area) (right).
(B) Lysosome function was analysed using Lysotracker Red and (C) DQ-BSA. DQ-BSA requires enzymatic cleavage in acidic lysosomal com-
partments to generate a highly fluorescent product. (D) Mitochondria of control and Patient HSP84.II.2-derived fibroblasts were stained with
MitoTracker, and mitochondrial circularity is shown on the right. (E) We used the mitochondrial-specific dye MitoTracker Deep RED FM, which
binds mitochondrial membrane independently of the membrane potential, and thus staining intensity has been considered an index of mito-
chondrial mass (MFI, mean fluorescence intensity). (F) Tetra-methylrhodamine (TMRM, 1mM) treatment for quantifying changes in mitochondrial
membrane potential. For A and D data are represented by average  standard error of the mean. For B, C, E and F data are represented by
average  SD. §t-test P = 0.009, **P5 0.05; ***P5 0.001; NS = not significant. Scale bar = 10 mm.
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signiﬁcant increase in mitochondrial mass with an overall
reduction in mitochondrial membrane potential (Fig. 3E
and F), in line with a previous report (Grunewald et al.,
2012).
Ultrastructural analysis of Thr512Ile-HSP ﬁbroblasts con-
ﬁrmed an excessive accumulation of lysosomes compared
to control cells (Fig. 4A and B). Strikingly, the majority of
the lysosomes in Thr512Ile-HSP cells contained abnormal
storage material consisting of whirls and stacks of mem-
branes (Fig. 4C–F), a lysosomal content that was almost
never observed in control cells (Fig. 4G).
Known recessive mutations in ATP13A2 causing KRS are
considered to be loss-of-function alleles. Some of them
lead to aberrant transcripts, which are destroyed by
Figure 4 Ultrastructure of cultured Thr512Ile-HSP fibroblasts. Lysosomes are excessively present in Thr512Ile-HSP fibroblasts (A)
compared to controls (B). The majority of lysosomes contain aberrant storage material consisting of whirls and stacks of membranes (C), in some
cases forming fingerprint bodies (D) or large clusters of membrane containing vesicles (E). In addition, cytoplasmic inclusions of tightly packed
membranes were frequently observed (F). In contrast, the content of lysosomes in control fibroblasts consisted of a normal mix of material (G).
Scale bars = 500 nm, except in F = 100 nm.
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nonsense-mediated mRNA decay (NMD), while others
impair protein stability, leading to mislocalization of
ATP13A2 to the endoplasmic reticulum and proteasomal
degradation (Ramirez et al., 2006; Park et al., 2011,
2014; Dehay et al., 2012; Podhajska et al., 2012;
Usenovic et al., 2012). p.Gln122 and p.Arg444 are pre-
dicted to be null alleles that are most likely prone to NMD,
whereas the p.Gln1135 may potentially escape NMD. This
mutation lies in the last exon and likely leads to a truncated
protein lacking 40 C-terminal amino acid residues. In con-
trast, according to in silico predictions the missense
p.Thr512Ile mutation may have little impact on protein
folding/stability (Phyre2; Kelley et al., 2015).
To assess stability of the ATP13A2 mutants in vitro,
COS-1 cells were transiently transfected with constructs allow-
ing expression of wild-type, Thr512Ile or Gln1135 followed
by analysis of the levels of mutant proteins. We compared the
HSP mutants to previously identiﬁed KRS mutant with com-
promised (Phe182Ile) ATP13A2 stability or early-onset parkin-
sonism mutant with preserved (Gly528Arg) ATP13A2 stability
(Podhajska et al., 2012) (Fig. 5A). All wild-type and mutant
ATP13A2 forms were successfully expressed, although reduced
protein levels were observed for Phe177Leu, in line with an
earlier report (Podhajska et al., 2012) (Fig. 5A). Putative deg-
radation of the ATP13A2 mutants through the proteasomal
pathway was evaluated using the proteasomal inhibitor
MG132 (Fig. 5B). Protein levels of all ATP13A2 variants
increased upon MG132 treatment, suggesting partial break-
down by the proteasome. However, the per cent difference
in expression levels between non-treated and MG132 condi-
tions were similar for wild-type as for all mutant constructs.
As the p.Thr512Ile substitution targets a residue within
the autophosphorylation motif (Fig. 1B), we questioned its
effect on autophosphorylation activity. We compared the
autophosphorylation levels of wild-type and disease mu-
tants in total membrane fractions of transiently transfected
COS-1 cells (Fig. 5C and D). In contrast to wild-type and
Gly528Arg, the Thr512Ile protein was unable to undergo
autophosphorylation, although it was expressed to compar-
able levels (Fig. 5A and D). In addition, we could not detect
an autophosphorylation signal for Gln1135 (Fig. 5C) even
when we increased the loading to reach comparable protein
levels of wild-type and Gln1135 (data not shown). No
signal was observed for the Phe177Leu mutant, but this
can be attributed to the weak expression levels and/or a
loss of autophosphorylation activity (Fig. 5D).
Finally, we evaluated the subcellular localization of the
GFP-N-ATP13A2 mutants transiently expressed in HeLa
cells (Fig. 5E and Supplementary Fig. 4). We ﬁrst conﬁrmed
that wild-type ATP13A2 co-localizes with LysoTracker-
labelled vesicles, whereas the KRS mutant Phe177Ile is mis-
localized to the endoplasmic reticulum (Podhajska et al.,
2012). The two novel HSP mutants were also mislocalized
to the endoplasmic reticulum, as we observed co-localiza-
tion of mutant proteins with the endoplasmic reticulum
marker pCI-mRuby-KDEL (Supplementary Fig. 3). This
suggests that, besides protein instability and inactivity,
also mistargeting contributes to the loss-of-function of
ATP13A2 in complicated HSP and KRS.
Discussion
Clinical spectrum of ATP13A2-
related diseases
Loss of ATP13A2 function has been linked to KRS, an
early-onset atypical form of Parkinson’s disease with de-
mentia that has been considered among the NBIA syn-
dromes (Micheli et al., 2006; Ramirez et al., 2006;
Djarmati et al., 2009; Rakovic et al., 2009), and the lyso-
somal storage disorder NCL (Bras et al., 2012). Here, we
report three novel nonsense and one missense mutations in
ATP13A2 in three families diagnosed with complicated
HSP for which we demonstrate loss of functionality.
Clinically, the HSP phenotype associated with ATP13A2
mutations (SPG78) is reminiscent of the phenotype
described for SPG11/15 and SPG48, with spastic paraple-
gia, cerebellar ataxia, cognitive deﬁcits and axonal neur-
opathy being common features in both SPG78 and
SPG11/15/48. Of note, SPG11/15 and SPG48 also fre-
quently display extrapyramidal disease manifestations
(Anheim et al., 2009; Schicks et al., 2011; Hirst et al.,
2016). The ‘ear of the lynx’ sign (T2 hyperintensity of the
anterior fornix of the corpus callosum), an imaging feature
described for SPG11 (Riverol et al., 2009) and SPG48
(Hirst et al., 2016), was also identiﬁed in two of ﬁve
SPG78 cases in our study. However, the age of onset ap-
pears to be later in SPG78, neither lenticular nor retinal
abnormalities were noted in SPG78, and thinning of the
corpus callosum, a hallmark imaging ﬁnding in SPG11,
15 and 48 was present in only one of our cases.
When considered from a clinical diagnostic standpoint,
the phenotypes associated with ATP13A2 mutations—
KRS, NCL and HSP—appear independent, but this stand-
point is now challenged by the discovery of a common
genetic aetiology, i.e. loss-of-function mutations in overlap-
ping regions or even identical sites in ATP13A2 (Fig. 6A).
KRS, HSP and NCL were each deﬁned before their re-
spective genetic basis was uncovered. Despite being multi-
systemic and thus clinically complex disorders, they were
classiﬁed according to their most striking feature. The
prominent parkinsonism seen in KRS families due to mu-
tations in ATP13A2, led to the classiﬁcation as an early-
onset Parkinson’s syndrome (PARK9) (Micheli et al., 2006;
Ramirez et al., 2006; Djarmati et al., 2009; Rakovic et al.,
2009). Additionally, the KRS phenotype is considered to be
part of the NBIA spectrum of disease due to the presence of
iron accumulation in the putamen and caudate of at least a
subset of cases (Schneider et al., 2013). The discovery of
lipopigment inclusions in another family with ATP13A2
mutations, which were also seen in mice and dogs with
ATP13A2 loss of function (Farias et al., 2011; Schultheis
298 | BRAIN 2017: 140; 287–305 A. Estrada-Cuzcano et al.
et al., 2013), led to the classiﬁcation as NCL (CLN12).
Here, we report that in three families with loss of
ATP13A2 function lower-limb predominant spastic para-
paresis is by far the most prominent clinical feature and
thus, the disease was classiﬁed as an HSP and termed
SPG78 (preliminary) (Gray et al., 2015). Extrapyramidal
involvement, the lead clinical symptom in KRS, was sub-
clinical (Patient HIH21480.II.3), subtle (Patient
HIH22132.II.1) or even absent (Family HSP84) in our
cases. Why the clinical consequences of ATP13A2
Figure 5 Expression levels and subcellular localization of wild-type and mutant ATP13A2. (A) Relative expression levels of
ATP13A2 WT, Phe177Ile, Thr512Ile, Gly528Arg and Gln1135, which were normalized to wild-type (WT) in COS-1 cells. (B) Expression levels of
ATP13A2 WT, Phe177Ile, Thr512Ile, Gly528Arg and Gln1135 in COS-1 cells following MG132 treatment were normalized to the levels without
MG132 treatment. (C) Semi-quantitative western blotting of ATP13A2 WT, Phe177Ile, Thr512Ile, Gly528Arg and Gln1135 overexpressed in
COS-1 cells, which were either treated ( + ) or not treated () with proteasome inhibitor MG132. EP (phospho-enzyme) represents the
autoradiogram displaying the relative autophosphorylation levels of wild-type and mutant ATP13A2. (D) Graph bar representing the ratio of the
autophosphorylation and expression levels (EP/WB). For A, B and D data are represented by average  SD. ANOVA test with post hoc
Bonferroni correction, §P = 0.01, **P5 0.001 with respect to wild-type with no treatment; #P5 0.001 with respect to wild-type treated with
MG132. NS = not significant. (E) Subcellular localization of GFP-N-ATP13A2 WT, Phe177Ile, Thr512Ile and Gln1135 mutant proteins, transiently
expressed in HeLa cells and stained with LysoTracker. Scale bar = 10 mm.
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mutations diverge remains unclear. Of interest, the same
p.Thr512Ile substitution that causes a complicated HSP
phenotype has previously been identiﬁed in a Lebanese
KRS patient (Dehay et al., 2012; Grunewald et al., 2012;
Usenovic et al., 2012), suggesting that the mutation type is
not the sole determinant of the clinical phenotype. The
Lebanese KRS patient presented with rapidly progressive
parkinsonism, supranuclear gaze palsy, perioral myokymia,
Figure 6 Clinical spectrum of ATP13A2 mutations. (A) Schematic representation of the genomic and protein lay out of ATP13A2 and
location of currently known disease-associated mutations. Topology of ATP13A2 represents 10 transmembrane domains (1–10) and an additional
membrane-associated segment in the N-terminus (a). In black, mutations associated with KRS; in green, mutations associated with early-onset
parkinsonism (EOPD); in blue, mutation associated with NCL; in red, mutations identified in this study, which are associated with complicated
HSP. (B) Schematic representation of the neuronal systems affected by ATP13A2 dysfunction and resulting signs and symptoms apparent on a
clinical level. Loss of ATP13A2 function in the cortex, extrapyramidal system, brainstem, pyramidal system, cerebellum, and the peripheral nerves
leads to a variety of signs and symptoms including dementia, parkinsonism, vertical gaze palsy, spasticity, ataxia, and peripheral neuropathy.
Predominance of extrapyramidal involvement or spasticity has led to the classification of ATP13A2-related disease as parkinsonism or HSP,
respectively. We hypothesize that other carriers of ATP13A2 mutations might display predominance of other ATP13A2-dependent systems and
therefore manifest as cerebellar ataxia, dementia or Charcot–Marie–Tooth disease.
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and cognitive decline at the age of 44 years. Notably, as
described in previously reported KRS patients (Williams
et al., 2005) and personal observation in the original
Chilean family (Ramirez et al., 2006), this patient also
had pyramidal involvement with marked spasticity and
hyperreﬂexia, most pronounced in the lower limbs, but
no ataxia. It is clear that much is yet to be learned about
which additional factors—genetic or environmental—
contribute to the individual presentation of disease in
these families.
Nevertheless, under the surface of the seemingly disparate
clinical diagnostic classiﬁcation of ATP13A2-related disease
into the categories of parkinsonism/NBIA, NCL or HSP,
the phenotypic features associated with ATP13A2 deﬁ-
ciency actually converge. Affection of various regions
and/or systems of the nervous system (cortical, pyramidal,
extrapyramidal, brainstem, cerebellar and peripheral) by
loss of ATP13A2 function translates phenotypically into a
multidimensional spectrum of associated signs and symp-
toms including dementia, spasticity, parkinsonism, disturb-
ance of the saccadic eye movement system, ataxia, and
peripheral neuropathy (Fig. 6B). The quantitative expres-
sion, not the qualitative presence of these features has his-
torically led us to determine diagnosis. While this approach
may still be useful in clinical practice for pragmatic reasons,
rigid diagnostic classiﬁcation systems may hamper identiﬁ-
cation of the underlying genetic cause. Thinking outside the
box of diagnostic classiﬁcations is needed to recognize
genes associated with more ﬂuid, multidimensional pheno-
types like ATP13A2, PNPLA6 (Synofzik et al., 2014), VCP
(Kazamel et al., 2016), BICD2 (Neveling et al., 2013;
Oates et al., 2013; Peeters et al., 2013), SPG11
(Guidubaldi et al., 2011; Daoud et al., 2012;
Montecchiani et al., 2016), DYNC1H1 (Vissers et al.,
2010; Weedon et al., 2011; Harms et al., 2012), TUBB4
(Erro et al., 2015), SYNE1 (Synofzik et al., 2016) and
others. We predict that the increasing use of unbiased
and ‘modular’ methods for phenotyping, e.g. by application
of the Human Phenotype Ontology (Kohler et al., 2014), in
combination with unbiased genetic screening methods such
as whole exome and whole genome sequencing will un-
cover many more Mendelian disease spectra crossing his-
torically deﬁned diagnostic categories in the future.
Several ATP13A2 HSP and KRS
mutants are mistargeted, unstable
and/or inactive
As in previous studies (Dehay et al., 2012; Grunewald
et al., 2012; Podhajska et al., 2012; Usenovic et al.,
2012), we conﬁrm that the loss-of-function of ATP13A2
in disease mutants relates to a combination of protein in-
stability and abnormal intracellular localization. Moreover,
here we provide the ﬁrst biochemical evidence demonstrat-
ing that HSP- and some KRS-causing ATP13A2 mutations
impair autophosphorylation activity, at least in part
explaining their loss-of-function. All P-type transport
ATPases couple the autophosphorylation reaction to the
vectorial transport of (a) ligand(s) over biological mem-
branes, indicating that the impaired autophosphorylation
of ATP13A2 might reﬂect defective substrate transport.
Alternatively, like other P-type ATPases (Pierre and Xie,
2006), ATP13A2 may play a scaffolding role in signalling
complexes, which might be regulated by autophosphoryla-
tion. Defects in one or both functionalities might be dis-
ease-causing.
The p.Thr512Ile mutation (HSP and KRS) impairs
ATP13A2 autophosphorylation activity, which together
with mistargeting of the mutant protein contributes to its
loss of function. Thr512 is part of the highly conserved
autophosphorylation motif (508D-K-T-G-T), which is pre-
sent in all P-type transport ATPases. Thr512 is positioned
in the catalytic centre in between the autophosphorylation
site Asp508 and the Mg2+ binding residue Thr510. Similar
to the Thr512Ile mutation in ATP13A2, the Thr512Ala
mutation of the equivalent residue in the Ca2+-pump
SERCA1a (Thr355), one of the archetypical P-type
ATPases, also impairs autophosphorylation and substrate
occlusion (McIntosh et al., 1999), notably without affecting
protein stability (Maruyama et al., 1989).
The loss-of-autophosphorylation activity of the Gln1135
mutant (HSP) might indicate that the C-terminus of
ATP13A2 is functionally important, as is the case for
other P-type ATPases (Vandecaetsbeek et al., 2009).
However, the low protein abundance and failure to exit
the endoplasmic reticulum, rather suggests that this
mutant is improperly folded and efﬁciently degraded.
Indeed, the truncation of ATP13A2 at the border of the
cytosolic end of transmembrane segment M10 might dis-
turb the membrane topology.
Lysosomal and mitochondrial
dysfunctions are common features in
HSP and KRS
Why ATP13A2 loss-of-function is implicated in a spectrum
of neuronal disorders remains unclear, but the deﬁciency of
this late endo-/lysosomal P-type transporter triggers lyso-
somal abnormalities (Chen et al., 2011; Park et al., 2011;
Dehay et al., 2012; Grunewald et al., 2012; Podhajska
et al., 2012; Usenovic and Krainc, 2012; Kong et al.,
2014). Fibroblasts derived from the Thr512Ile KRS patient
are marked by general lysosomal dysfunction as observed
by the accumulation of lysosomes, impaired autophagy,
reduced lysosomal proteolysis and increased lysosomal
pH (Dehay et al., 2012; Gusdon et al., 2012; Ramonet
et al., 2012; Usenovic et al., 2012). Here, we conﬁrm in
ﬁbroblasts of unrelated HSP and KRS patients that
LAMP1-positive organelles accumulate, correlating with a
reduction in their proteolytic activity. Thus, an increased
number of LAMP1-positive organelles may be a hallmark
of ATP13A2 dysfunction. Ultrastructural analysis revealed
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deposition of abnormal lysosomal storage material in the
form of lipid whorls and stacks of membranes.
Interestingly, a similar lysosomal phenotype has previously
been reported for three other subtypes of HSP: SPG11 (spa-
tacsin), SPG15 (ZFYVE26/spastizin) and SPG48 (AP5Z1/
AP-5). In all three, accumulation of LAMP1-positive organ-
elles was described in primary patient ﬁbroblasts
(Vantaggiato et al., 2013; Chang et al., 2014; Renvoise
et al., 2014; Hirst et al., 2016). Loss of SPG11/SPG15 re-
sults in the depletion of free lysosomes and an accumula-
tion of autolysosomes due to impaired lysosome
reformation, an mTOR dependent pathway (Chang et al.,
2014). Furthermore, ﬁbroblasts of patients with mutations
in the SPG15- or SPG48 gene display multilamellar accu-
mulation of membranous material similar to those we ob-
serve in ATP13A12 mutant ﬁbroblasts (Renvoise et al.,
2014; Hirst et al., 2016). These ﬁndings therefore suggest
a molecular link between these four HSP subtypes that is
particularly interesting in light of the clinical and imaging
overlap (see above).
Neurons depend heavily on mitochondrial clearance
pathways to preserve mitochondrial health, which on
itself rests on efﬁcient lysosomal function. Like lysosomal
dysfunction, impaired mitochondrial function is implicated
in NCL (Pezzini et al., 2011; Vidal-Donet et al., 2013),
HSP (Casari et al., 1998; Hansen et al., 2002; Patel
et al., 2002; Verny et al., 2011; Arif et al., 2013) or KRS
(Grunewald et al., 2012; Park et al., 2014), and several
studies connect ATP13A2 to mitochondrial clearance
(Grunewald et al., 2012; Gusdon et al., 2012; Holemans
et al., 2015; Martin et al., 2016). Mitochondrial fragmen-
tation and impaired ATP production were previously
described in the Thr512Ile-KRS ﬁbroblasts (Grunewald
et al., 2012). Although we did not observe signiﬁcant
changes in the morphology of the mitochondrial network
in the ﬁbroblasts of either the HSP or KRS patients, the
reduction in the mitochondrial membrane potential sug-
gests impaired mitochondrial functionality that may result
in lower ATP levels. Moreover, the increased mitochondrial
mass might point to an impaired mitochondrial clearance,
which might be connected to the ATP13A2-mediated lyso-
somal dysfunction. In fact, ATP13A2 has been implicated
in autophagy pathways (Dehay et al., 2012; Grunewald
et al., 2012; Podhajska et al., 2012; Usenovic et al.,
2012) and also the activation of ATP13A2 by the phospho-
lipids phosphatidic acid and phosphatidylinositol(3,5)bi-
sphosphate suggests a role in autophagy (Holemans et al.,
2015; Martin et al., 2015). Interestingly, genetic defects in
the pathways controlling phospholipid homeostasis, like
phosphatidic acid, have been previously implicated in
HSP. Mutations in two phospholipases (DDHD1 and
DDHD2) cause SPG28 and SPG52 HSP subtypes, respect-
ively. Defects in these enzymes lead to lipid accumulation
and disturbed intracellular trafﬁcking (Schuurs-
Hoeijmakers et al., 2012; Tesson et al., 2012; Gonzalez
et al., 2013).
In conclusion, loss of ATP13A2 function causes a com-
bination of lysosomal and mitochondrial dysfunction that
affects multiple neuronal populations. This translates to a
spectrum of neurological disorders ranging from compli-
cated HSP to KRS. We propose that patients with compli-
cated HSP should be routinely tested for ATP13A2
mutations, in particular if complicated by progressive cog-
nitive and cerebellar dysfunction.
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